Opus Genetics FY2026 EPS Estimate Boosted by HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS estimate for Opus Genetics to a loss of $1.03 per share from a projected loss of $1.18, while maintaining a “Buy” rating and an $8 price target.
• Opus Genetics reported a quarterly loss of $0.14 per share, beating expectations by $0.02, but revenue of $0.76 million fell well short of the $2.63 million analyst consensus.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and average price target of $10.69; however, insiders have sold roughly $7.5 million of stock over the past three months.

Opus Genetics, Inc. (NASDAQ:IRD - Free Report) - HC Wainwright raised their FY2026 earnings estimates for shares of Opus Genetics in a report issued on Monday, August 10th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($1.03) per share for the year, up from their prior forecast of ($1.18). HC Wainwright has a "Buy" rating and a $8.00 price objective on the stock. The consensus estimate for Opus Genetics' current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Opus Genetics' Q4 2026 earnings at ($0.09) EPS, FY2027 earnings at ($0.40) EPS, FY2028 earnings at ($0.16) EPS, FY2029 earnings at $0.05 EPS and FY2030 earnings at $0.27 EPS.

Opus Genetics (NASDAQ:IRD - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. Opus Genetics had a negative net margin of 1,091.82% and a negative return on equity of 338.88%. The firm had revenue of $0.76 million during the quarter, compared to analysts' expectations of $2.63 million.

Several other research firms have also recently weighed in on IRD. Guggenheim assumed coverage on shares of Opus Genetics in a research report on Thursday, June 4th. They issued a "buy" rating and a $16.00 price objective for the company. Chardan Capital reiterated a "buy" rating and issued a $13.00 price objective on shares of Opus Genetics in a research report on Monday, July 6th. TD Cowen began coverage on Opus Genetics in a research note on Wednesday, July 29th. They issued a "buy" rating for the company. Wall Street Zen raised Opus Genetics from a "strong sell" rating to a "sell" rating in a research note on Saturday. Finally, Citizens Jmp reaffirmed a "market outperform" rating and set a $11.00 price target on shares of Opus Genetics in a research note on Monday, June 15th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $10.69.

Opus Genetics Price Performance

IRD opened at $3.88 on Wednesday. Opus Genetics has a one year low of $1.04 and a one year high of $5.81. The company's 50 day simple moving average is $3.80 and its 200-day simple moving average is $4.14. The stock has a market capitalization of $320.68 million, a P/E ratio of -2.87 and a beta of 0.59.

Insider Buying and Selling

In other Opus Genetics news, CEO George Magrath sold 9,475 shares of the company's stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total transaction of $27,951.25. Following the completion of the sale, the chief executive officer owned 1,731,869 shares in the company, valued at approximately $5,109,013.55. The trade was a 0.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 1,700,000 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $4.35, for a total value of $7,395,000.00. Following the completion of the transaction, the director directly owned 3,792,171 shares in the company, valued at approximately $16,495,943.85. This trade represents a 30.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 1,729,331 shares of company stock valued at $7,481,629. 11.70% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Opus Genetics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IRD. Texas Capital Bank Wealth Management Services Inc acquired a new position in Opus Genetics in the second quarter valued at about $504,000. BlackRock Inc. bought a new position in Opus Genetics during the second quarter worth about $12,809,000. Deutsche Bank AG acquired a new position in shares of Opus Genetics during the 2nd quarter worth about $219,000. Bank of New York Mellon Corp acquired a new position in shares of Opus Genetics during the 2nd quarter worth about $503,000. Finally, State of Wyoming bought a new stake in shares of Opus Genetics in the 2nd quarter valued at about $65,000. Institutional investors own 14.97% of the company's stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source